回盛生物(300871.SZ):“土苓茅根顆粒”獲得新獸藥註冊證書
格隆匯 9 月 16日丨回盛生物(300871.SZ)公佈,根據《獸藥管理條例》和《獸藥註冊辦法》規定,經農業農村部審查,批准公司全資子公司湖北迴盛生物科技有限公司(“湖北迴盛”)與其他單位聯合申報的“土苓茅根顆粒”為三類新獸藥,並於近日核發了《新獸藥註冊證書》(農業農村部公告第327號)。
新獸藥名稱:土苓茅根顆粒;研製單位:湖北迴盛生物科技有限公司、青島動保國家工程技術研究中心有限公司、石家莊江山動物藥業有限公司、山東欣慧瑞生物科技有限公司、廣東海納川生物科技股份有限公司、山東省獸藥質量檢驗所、青島蔚藍生物股份有限公司、成都新精華藥業有限公司、石家莊市金元康牧藥業有限公司、青島信諾邦生物科技有限公司、江西邦誠動物藥業有限公司。新獸藥註冊證書號:(2020)新獸藥證字37號;註冊分類:三類;主要成分:土茯苓、白茅根等。作用與用途:清熱利濕,健脾化濁。用於濕熱及飼料蛋白質含量過高引起的腎腫濕熱證。用法與用量:混飲,每1L水,雞1g,每日2次,連用5天。
中獸藥由於具有綠色環保、無藥殘等優勢,成為畜禽疫病防控研究的熱點。目前治療雞腎臟疾病的有國家標準的中藥方劑較少,隨着人們對健康養殖的逐漸重視,此類藥物的市場需求必將逐漸提高。
臨牀試驗結果表明,土苓茅根顆粒對雞腎損傷的臨牀治療效果較好。該製劑臨牀治療中至今未發現有嚴重的毒副作用,已有的藥理學研究以及臨牀研究結果均證實了該產品安全有效。
新獸藥證書的取得是公司持續重視科技創新、加大研發投入的結果,進一步體現了公司的創新能力,也是公司積極推進技術市場化的成果。土苓茅根顆粒主要用於濕熱及飼料蛋白質含量過高引起的腎腫濕熱證,降低家禽養殖成本,護航健康養殖,同時為公司的業務帶來新的業績增長點。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.